Towa Pharmaceutical Co., Ltd. (TYO:4553)
3,950.00
+90.00 (2.33%)
May 29, 2026, 3:30 PM JST
Towa Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 45,306 | 45,471 | 29,650 | 24,257 | 32,830 |
Cash & Short-Term Investments | 45,306 | 45,471 | 29,650 | 24,257 | 32,830 |
Cash Growth | -0.36% | 53.36% | 22.23% | -26.11% | 43.27% |
Receivables | 74,002 | 71,631 | 71,657 | 54,392 | 50,748 |
Inventory | 123,425 | 108,287 | 101,072 | 92,927 | 72,701 |
Other Current Assets | 24,610 | 21,917 | 15,339 | 11,414 | 10,585 |
Total Current Assets | 267,343 | 247,306 | 217,718 | 182,990 | 166,864 |
Property, Plant & Equipment | 170,643 | 168,423 | 153,642 | 127,004 | 100,857 |
Long-Term Investments | 4,486 | 3,213 | 3,006 | 3,104 | 3,035 |
Goodwill | 9,468 | 28,115 | 32,568 | 34,613 | 44,647 |
Other Intangible Assets | 17,212 | 17,727 | 18,018 | 18,332 | 9,455 |
Long-Term Deferred Tax Assets | 6,136 | 6,037 | 5,699 | 5,303 | 5,075 |
Other Long-Term Assets | 2 | 2 | 2 | 1 | 2 |
Total Assets | 475,290 | 470,823 | 430,653 | 371,347 | 329,935 |
Accounts Payable | 33,343 | 30,041 | 26,372 | 36,070 | 29,076 |
Accrued Expenses | 97 | 112 | 96 | 117 | 108 |
Short-Term Debt | 9,317 | 10,057 | 6,927 | 15,224 | 52,762 |
Current Portion of Long-Term Debt | 21,772 | 18,023 | 10,120 | 7,527 | 12,172 |
Current Portion of Leases | 1,699 | 1,383 | - | - | - |
Current Income Taxes Payable | 22,056 | 20,334 | 23,911 | 14,012 | 15,536 |
Other Current Liabilities | 8,583 | 7,989 | 12,692 | 5,579 | 5,419 |
Total Current Liabilities | 96,867 | 87,939 | 80,118 | 78,529 | 115,073 |
Long-Term Debt | 183,335 | 195,077 | 189,124 | 150,314 | 79,194 |
Long-Term Leases | 12,829 | 11,801 | - | - | - |
Pension & Post-Retirement Benefits | 132 | 141 | 220 | 322 | 547 |
Other Long-Term Liabilities | 4,024 | 4,241 | 5,299 | 5,288 | 2,952 |
Total Liabilities | 297,187 | 299,199 | 274,761 | 234,453 | 197,766 |
Common Stock | 4,717 | 4,717 | 4,717 | 4,717 | 4,717 |
Additional Paid-In Capital | 7,842 | 7,841 | 7,838 | 7,837 | 7,837 |
Retained Earnings | 151,815 | 150,502 | 134,452 | 121,232 | 122,131 |
Treasury Stock | -5,584 | -5,586 | -5,606 | -5,608 | -5,608 |
Comprehensive Income & Other | 19,313 | 14,150 | 14,491 | 8,716 | 3,092 |
Shareholders' Equity | 178,103 | 171,624 | 155,892 | 136,894 | 132,169 |
Total Liabilities & Equity | 475,290 | 470,823 | 430,653 | 371,347 | 329,935 |
Total Debt | 228,952 | 236,341 | 206,171 | 173,065 | 144,128 |
Net Cash (Debt) | -183,646 | -190,870 | -176,521 | -148,808 | -111,298 |
Net Cash Per Share | -3730.55 | -3877.50 | -3586.33 | -3023.21 | -2211.60 |
Filing Date Shares Outstanding | 49.23 | 49.23 | 49.22 | 49.22 | 49.22 |
Total Common Shares Outstanding | 49.23 | 49.23 | 49.22 | 49.22 | 49.22 |
Working Capital | 170,476 | 159,367 | 137,600 | 104,461 | 51,791 |
Book Value Per Share | 3617.93 | 3486.37 | 3167.24 | 2781.16 | 2685.17 |
Tangible Book Value | 151,423 | 125,782 | 105,306 | 83,949 | 78,067 |
Tangible Book Value Per Share | 3075.96 | 2555.14 | 2139.49 | 1705.52 | 1586.02 |